Overview

Study of the Safety, Pharmacodynamics and Efficacy of KRN23 in Children From 1 to 4 Years Old With X-linked Hypophosphatemia (XLH)

Status:
Active, not recruiting
Trial end date:
0000-00-00
Target enrollment:
Participant gender:
Summary
UX023-CL205 is a multicenter, open-label, Phase 2 study in children from 1 to 4 years old with XLH to assess the safety, PD, and efficacy of KRN23 administered via subcutaneous (SC) injections every 2 weeks (Q2W) for a total of 64 weeks.
Phase:
Phase 2
Details
Lead Sponsor:
Ultragenyx Pharmaceutical Inc